Colorectal cancer or colon and rectal cancer? Clinicopathological comparison between colonic and rectal carcinomas.
OBJECTIVE
The aim of this study was to compare features of colon and rectal cancers such as prognosis, clinicopathological features and tumor markers, namely carcinoembryonic antigen (CEA), matrix metalloproteinase (MMP)-2 and p27(kip1).


METHODS
Two hundred and thirty patients with stage I-III colon or rectal cancer were retrospectively assessed with the endpoint of recurrence or metastasis after curative operation. CEA, MMP-2 and p27(kip1) were studied by immunohistochemistry in cancer tissues of all patients.


RESULTS
The disease-free 3-year survival rate after operation of the total 230 patients was 63.0%. The prognosis of colon cancer was significantly better than that of rectal cancer (70.6 vs. 57.0%; p = 0.017), especially for stage III (p = 0.0059). Multivariate analysis also demonstrated that tumor location in the colon or rectum, differentiation, venous invasion and the expression of CEA were independent factors for prognosis. The hazard of recurrence and metastasis in rectal cancer was 1.564 times that in colon cancer. In both groups, there were no statistical differences in age, gender, tumor size, tumor gross type, mucin production, tumor differentiation, venous invasion, MMP-2 and p27(kip1).


CONCLUSIONS
We investigated prognosis, clinicopathological factors, oncogenes and tumor suppressor gene production in colon and rectal cancers. The prognosis of colon cancer is better than that of rectal cancer, especially for stage III. This study shows some differences between colon and rectal cancer.
Li
M
M
Gastrointestinal Surgery Unit, Peking University School of Oncology, Beijing Cancer Hospital & Institute, Beijing, China.
Li
J Y
JY
Zhao
A L
AL
Gu
J
J
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000704:Analysis of Variance; D014408:Biomarkers, Tumor / Q000032:analysis*; D002272:Carcinoembryonic Antigen / Q000032:analysis*; D003110:Colonic Neoplasms / Q000737:chemistry / Q000235:genetics / Q000401:mortality / Q000473:pathology*; D050760:Cyclin-Dependent Kinase Inhibitor p27; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D047908:Intracellular Signaling Peptides and Proteins / Q000032:analysis*; D053208:Kaplan-Meier Estimate; D008297:Male; D020778:Matrix Metalloproteinase 2 / Q000032:analysis*; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D016017:Odds Ratio; D011237:Predictive Value of Tests; D011379:Prognosis; D012004:Rectal Neoplasms / Q000737:chemistry / Q000235:genetics / Q000401:mortality / Q000473:pathology*; D012189:Retrospective Studies
D014408:Biomarkers, Tumor; C436291:CDKN1B protein, human; D002272:Carcinoembryonic Antigen; D047908:Intracellular Signaling Peptides and Proteins; D050760:Cyclin-Dependent Kinase Inhibitor p27; D020778:Matrix Metalloproteinase 2